Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
The antimicrobial activity of the new fluoroquinolone rufloxacin (MF 934) was evaluated by a standardized agar dilution method against recent clinical isolates of Salmonella typhi (67 strains) and Brucella melitensis (108 isolates). The results were compared with 5 other commercially available or investigational fluoroquinolones. All the isolates of S. typhi were inhibited by 1.0 mg/l of rufloxacin as compared to 4-8 mg/l for B. melitensis. Minimum inhibitory concentrations of rufloxacin against both S. typhi and B. melitensis were 4-16 times higher than those of other fluoroquinolones.
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
S M
SM
Qadri
A
A
Ayub
Y
Y
Ueno
H
H
Saldin
D000890:Anti-Infective Agents / Q000494:pharmacology*; D017347:Brucella melitensis / Q000187:drug effects*; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D015363:Quinolones / Q000494:pharmacology*; D012485:Salmonella typhi / Q000187:drug effects*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C060328:rufloxacin